Business Description
Royalty Pharma PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BMVP7Y09
Share Class Description:
RPRX: Class ACompare
Compare
Traded in other countries / regions
RPRX.USARPRX.MexicoRPD.Germany IPO Date
2020-06-16Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.2 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 0.94 | |||||
| Debt-to-EBITDA | 3.25 | |||||
| Interest Coverage | 7.97 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.02 | |||||
| Beneish M-Score | -3.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.6 | |||||
| 3-Year EBITDA Growth Rate | -14.5 | |||||
| 3-Year EPS without NRI Growth Rate | 30.7 | |||||
| 3-Year FCF Growth Rate | -2.9 | |||||
| 3-Year Book Growth Rate | 5.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 3.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.37 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.96 | |||||
| 9-Day RSI | 28.49 | |||||
| 14-Day RSI | 33.67 | |||||
| 6-1 Month Momentum % | 8.08 | |||||
| 12-1 Month Momentum % | -17.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.9 | |||||
| Quick Ratio | 7.9 | |||||
| Cash Ratio | 7.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.95 | |||||
| Dividend Payout Ratio | 0.4 | |||||
| 3-Year Dividend Growth Rate | 38.7 | |||||
| Forward Dividend Yield % | 3.05 | |||||
| 5-Year Yield-on-Cost % | 2.86 | |||||
| 3-Year Average Share Buyback Ratio | -4.8 | |||||
| Shareholder Yield % | 6.66 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 63.37 | |||||
| Net Margin % | 48.2 | |||||
| FCF Margin % | 126.89 | |||||
| ROE % | 18.59 | |||||
| ROA % | 6.82 | |||||
| ROIC % | 9.93 | |||||
| ROCE % | 11.87 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 10.97 | |||||
| Forward PE Ratio | 8.12 | |||||
| PE Ratio without NRI | 13.86 | |||||
| PS Ratio | 7.04 | |||||
| PB Ratio | 1.89 | |||||
| Price-to-Tangible-Book | 1.89 | |||||
| Price-to-Free-Cash-Flow | 5.61 | |||||
| Price-to-Operating-Cash-Flow | 5.61 | |||||
| EV-to-EBIT | 9.28 | |||||
| EV-to-Forward-EBIT | 7.99 | |||||
| EV-to-EBITDA | 9.28 | |||||
| EV-to-Forward-EBITDA | 7.99 | |||||
| EV-to-Revenue | 7.44 | |||||
| EV-to-Forward-Revenue | 6.74 | |||||
| EV-to-FCF | 5.86 | |||||
| Price-to-Graham-Number | 1.08 | |||||
| Earnings Yield (Greenblatt) % | 10.78 | |||||
| FCF Yield % | 24.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RPRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Royalty Pharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,354.554 | ||
| EPS (TTM) ($) | 2.52 | ||
| Beta | 0.36 | ||
| Volatility % | 16.48 | ||
| 14-Day RSI | 33.67 | ||
| 14-Day ATR ($) | 0.631182 | ||
| 20-Day SMA ($) | 29.6485 | ||
| 12-1 Month Momentum % | -17.02 | ||
| 52-Week Range ($) | 25.92 - 36.67 | ||
| Shares Outstanding (Mil) | 446.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Royalty Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Royalty Pharma PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Royalty Pharma PLC Frequently Asked Questions
What is Royalty Pharma PLC(RPRX)'s stock price today?
The current price of RPRX is $27.66. The 52 week high of RPRX is $36.67 and 52 week low is $25.92.
When is next earnings date of Royalty Pharma PLC(RPRX)?
The next earnings date of Royalty Pharma PLC(RPRX) is 2024-05-09 Est..
Does Royalty Pharma PLC(RPRX) pay dividends? If so, how much?
The Dividend Yield %  of Royalty Pharma PLC(RPRX) is 2.95% (As of Today), Highest Dividend Payout Ratio of Royalty Pharma PLC(RPRX) was 0.55. The lowest was 0.33. And the median was 0.41. The  Forward Dividend Yield % of Royalty Pharma PLC(RPRX) is 3.05%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers